Semax 10mg
Semax is a synthetic heptapeptide with the amino-acid sequence Met-Glu-His-Phe-Pro-Gly-Pro (MEHFPGP), derived from the active ACTH(4–7) sequence with a C-terminal Pro-Gly-Pro (PGP) extension for greater proteolytic stability. It is studied in neuropeptide research, neurotrophin signaling, BDNF and NGF expression, melanocortin biology, neuronal signaling, and neuroprotection
Compound information
What is the Peptide?
A seven-amino-acid peptide based on a fragment of adrenocorticotropic hormone, redesigned to keep its brain-supporting activity while dropping its hormonal role. Developed in Russia, it is studied mainly for raising levels of BDNF, a key neurotrophic factor in the brain.
Structure
Stability information
Product overview
A neurotrophic ACTH-analog research peptide supplied for laboratory evaluation at a ≥99% HPLC analytical standard.
Technical overview
Semax takes the ACTH(4-7) core of adrenocorticotropic hormone and replaces the rest with a Pro-Gly-Pro tail. That swap removes the parent's hormonal, corticotropic activity while making the peptide far more resistant to enzyme breakdown and preserving its effect on the nervous system.
It is produced by solid-phase synthesis and preparative purification, then released against a lot-matched Certificate of Analysis carrying HPLC purity and LC-MS identity.
Research applications
Semax is used as a tool for neurotrophic and neuroprotection research. Common laboratory work includes BDNF and NGF expression assays in hippocampal tissue, TrkB and TrkA signaling studies, cerebral-ischemia and stroke models, and research into dopaminergic and serotonergic modulation and cognitive-function endpoints in rodents.
Kylo Peptides supplies this compound as a reference material for scientific inquiry. All applications must be conducted by qualified professionals in controlled laboratory environments. It has not been evaluated by the FDA and is not intended to diagnose, treat, cure, or prevent any disease.
Frequently Researched Together
Frequently Asked Questions
It stabilizes the peptide. Semax keeps the active ACTH(4-7) core but caps it with a Pro-Gly-Pro tripeptide in place of the original ending. That tail resists the plasma enzymes that would quickly break the peptide down, and it removes the corticotropic hormone activity of the parent, leaving the neurotrophic effect behind.
Because raising BDNF is its most studied action. Brain-derived neurotrophic factor supports neuron survival and synaptic plasticity, and research in rodent models has reported that Semax quickly increases BDNF and NGF in the hippocampus, along with activation of their downstream TrkB and TrkA signaling. That mechanism underlies most of the neuroprotection research.
It came out of the Institute of Molecular Genetics at the Russian Academy of Sciences, where a team designed it from ACTH-fragment neuropeptides. In Russia it is a registered medicine for stroke and cognitive conditions, but it is not approved by the FDA and is handled elsewhere as a research compound.
Each lot is verified at ≥99% by HPLC, with mass spectrometry confirming identity. Independent third-party testing clears every batch before it ships, and the certificate for a given lot can be looked up by the number printed on the vial.
Cold and dry. Keep the lyophilized powder at −20 °C, sealed and out of light, with −80 °C better for long storage. After reconstitution, keep the solution at 2 to 8 °C, use it within a validated window, and avoid repeated freeze-thaw cycles.
No. Kylo supplies Semax as a characterized reagent for in vitro laboratory research only. It is not formulated or labeled for use in humans or animals, and it is provided strictly to qualified researchers for controlled experimental work.
Backed By A Lot-Matched COA
Every Semax order is tied to a certificate of analysis matched to the exact lot in your vial.
Shop catalog →
